ABSTRACT
BACKGROUND: The aim of the study is to improve the family relations of the patients who suffer for schizophrenia, to ensure the participation of the family in the treatment, to improve treatment compliance and to reduce relapse. SUBJECTS AND METHODS: A total of 80 caregivers of the patients, consisting of 40 people as a study group and 40 as a control group, the training was given in two sessions of forty five minutes twice a week, 24 sessions completed in approximately three months. It was applied in both groups at the beginning and end of the training the scales that are the test batteries. RESULTS: While there was no difference between the two groups according to the pre-test scores obtained before the family psychological training program, according to the post-test scores, there was a significant difference between two groups in terms of symptoms of depression and anxiety, solutionoriented coping, emotion-oriented coping, dangerous perception of the disease and emotion expression. CONCLUSION: The training programme thought that the family psychological training support to be given to the relatives of patients with schizophrenia will both contribute positively to the treatment and play an effective role in the adaptation of the caregivers' to the disease.
Subject(s)
Schizophrenia , Humans , Schizophrenia/therapyABSTRACT
PURPOSE: The aim of the study was to assess efficacy and safety of paliperidone palmitate (PP) in schizophrenic patients using real-life data. METHODS: This national, multicenter, retrospective, and mirror-image study was performed reviewing the medical records of patients in 18 centers. Adult schizophrenic patients receiving PP treatment (n = 205) were enrolled. Patients' data covering the last 12 months before the initial PP injection and the period until the end of study with at least 12 months after the initial PP injection were evaluated. Patients' characteristics, scale scores, and adverse events were recorded. RESULTS: Nonadherence to prior medication was the most frequent reason for switching to PP treatment. Comparing with the period before PP treatment, the rate of patients visiting the hospital for relapse (79.5% vs 28.9%, P < 0.001) and the median number of hospitalizations (2 vs 0, P < 0.001) were lower during PP treatment. During PP treatment, the Positive and Negative Syndrome Scale score decreased by 20% or more (response to treatment) in 75.7% of the patients. The frequency of adverse events did not differ between the period before and during PP treatment. Improvement in functionality was higher in those with disease duration of 5 years or less. CONCLUSIONS: Paliperidone palmitate is effective and safe in treatment of schizophrenic patients and in switching to PP treatment in patients with schizophrenia, which reduced the percentage of patients admitted to the hospital for relapse and the median number hospitalization, and has positive effects on functionality.
